SUPPRESSION OF PRIMARY T-CELL RESPONSES AND INDUCTION OF ALLOANTIGEN-SPECIFIC HYPORESPONSIVENESS IN VITRO BY THE JANUS KINASE INHIBITOR TYRPHOSTIN AG4901
- 1 October 2000
- journal article
- immunobiology
- Published by Wolters Kluwer Health in Transplantation
- Vol. 70 (8) , 1215-1225
- https://doi.org/10.1097/00007890-200010270-00016
Abstract
Tyrphostin AG490 has recently been shown to block interleukin (IL)-2 receptor gamma-chain-associated Janus kinase 3. Here, we analyzed the effect of AG490 on T-cell alloresponses in vitro. For the evaluation of T-cell activation, DNA synthesis, surface marker expression, cytokine secretion, intracellular calcium mobilization, early protein tyrosine phosphorylation, and apoptosis were measured. AG490 effectively inhibited T-cell proliferation in human mixed lymphocyte culture (MLC) even when added 4 days after culture initiation. Inhibition of IL-2-dependent proliferation in T-cell blasts and the incapability of IL-2 or IL-15 to restore proliferation in AG490-treated MLC suggests interference with cytokine receptor signaling. T-cell receptor-triggered early protein tyrosine phosphorylation, calcium mobilization, up-regulation of CD69, and initial CD25 expression were not affected. Interestingly, AG490 substantially inhibited production of IL-2 and interferon-gamma in T cells stimulated with alloantigen or via CD3 and CD28. In CD28-independent activation models (e.g., stimulation with phorbol myristate acetate plus ionomycin), however, cytokine secretion was not inhibited. Pretreatment of primary MLC with AG490 resulted in substantial down-regulation of secondary responses to cells from the original donor as opposed to third-party cells or phytohemagglutinin. Unresponsiveness was induced also in T cells stimulated with CD3 monoclonal antibody. Induction of apoptosis in polyclonally activated T cells and the incapability of IL-2 to reverse specific hyporesponsiveness, suggest programmed cell death as an important mechanism underlying antigen-specific down-regulation of alloresponses. We demonstrate that AG490 blocks different manifestations of T-cell activation. This and its ability to induce alloantigen-specific hyporesponsiveness point to a potential use for interfering with alloreactivities in vivo.Keywords
This publication has 32 references indexed in Scilit:
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitorNature, 1996
- Developmental defects of lymphoid cells in Jak3 kinase-deficient miceImmunity, 1995
- Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid DevelopmentScience, 1995
- Defects in B Lymphocyte Maturation and T Lymphocyte Activation in Mice Lacking Jak3Science, 1995
- Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chainImmunity, 1995
- Involvement of p21ras activation in T cell CD69 expressionEuropean Journal of Immunology, 1994
- A Cell Culture Model for T Lymphocyte Clonal AnergyScience, 1990
- Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitorsJournal of Medicinal Chemistry, 1989
- Phytohaemagglutinin activation of T cells through the sheep red blood cell receptorNature, 1985